 III. To evaluate the mRNA expression of enzymes in tumors of the patients entered on this study which may be important to the cytotoxicity of oxaliplatin ERCC1, mismatch repair, ribonucleotide reductase, bcl-2, bax, p53. An attempt will be made to obtain tumor biopsies from all patients. 